bioAffinity Technologies, Inc. — Director's Dealing 2024

Jan 25, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: bioAffinity Technologies, Inc. (BIAF)
CIK: 0001712762
Period of Report: 2023-10-01

Reporting Person: Rubin Gary D (Director, 10% Owner)
Reporting Person: Harvey Sandler Revocable Trust (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-10-01	Common Stock	A	11867	$1.58	Acquired	91849	Direct
2024-01-01	Common Stock	A	12668	$1.48	Acquired	104517	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1584144	Indirect

Footnotes

F1: Represents a grant from Issuer to Mr. Rubin of 11,867 restricted shares of Common Stock, on October 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.

F2: Represents a grant from the Issuer to Mr. Rubin of 12,668 restricted shares of Common Stock, on January 1, 2024 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year.

F3: Represents shares of Common Stock owned directly by the Harvey Sandler Revocable Trust (the "Trust"), a 10% owner of the Issuer, and indirectly by Mr. Rubin, as co-trustee of the Trust, which indirect ownership was previously reported on a Form 4 filed by Mr. Rubin and the Trust on October 21, 2022. Mr. Rubin disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.